AIM ImmunoTech Inc (AIM) has released an update to notify the public and investors about a regulation fd disclosure.
AIM ImmunoTech has announced positive preliminary results from a Phase 2 study on Ampligen’s effectiveness in treating post-COVID conditions, generating buzz among investors. A video interview with Dr. Chris McAleer, AIM’s Scientific Officer, discussing these findings is available for further insights on the Virtual Investor platform, signaling a potential breakthrough that could impact the company’s stock value. This development is not officially filed but is provided to the public for informational purposes.
For further insights into AIM stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
